Argenx presents Phase 3 data for VYVGART Hytrulo, a potential first advancement in chronic inflammatory demyelinating polyneuropathy in 30 years, at AAN Annual Meeting.
Argenx presents Phase 3 ADHERE trial data for VYVGART Hytrulo in chronic inflammatory demyelinating polyneuropathy patients at AAN Annual Meeting. VYVGART Hytrulo, combining efgartigimod alfa and hyaluronidase-qvfc, shows potential as first advancement in CIDP in 30 years. Real-world data also demonstrate gMG patients significantly reducing steroid use with VYVGART treatment.
April 16, 2024
3 Articles